Senores Pharmaceuticals Limited held its Q4 and FY25 Earnings Conference Call on May 16, 2025.
The company reported strong financial performance, with income from regulated markets growing 17% to ₹64 crore in Q4 FY25, and income from emerging markets at ₹37 crore.
Full-year income stood at ₹410 crore, a 91% increase over FY24, driven by both regulated and emerging market businesses.
Regulated market income grew 69% to ₹245 crore, while emerging market income surged 174% to ₹121 crore.
Consolidated EBITDA for FY25 showed a 145% increase, reaching ₹102 crore, with an EBITDA margin of 25%, up 540 basis points from FY24.
Profit after tax and minority interest for the year stood at ₹59 crore, an 86% increase over FY24.
The company acquired 14 ANDAs from Dr. Reddy's and one from Breckenridge, expanding its portfolio to 61 ANDA products, with 22 commercialized ANDAs as of March 31, 2025.
Senores plans to launch around 31 ANDA products in regulated markets and 23 CDMO-CMO products in the current financial year.
The CDMO-CMO segment has a pipeline of 69 products as of March 2025, with many expected to be commercialized during the fiscal year; the portfolio stands at about 22 products.
The company anticipates a revenue mix of approximately 70% from regulated markets and 30% from emerging markets, maintaining a sustainable margin in the range of 24% to 26% annually.
Management anticipates at least 50% top-line growth and 100% PAT growth for the next year.
Swapnil Shah, Managing Director, mentioned that the company is targeting at least 50% plus top-line growth and 100% growth in profit after tax (PAT) for the next year. He also noted that a revenue of approximately ₹15 crore, initially expected in Q4, was deferred due to packaging line issues and product launch delays.